FemPulse Receives FDA IDE Approval for the Pivotal Clinical Trial of its Wearable Bioelectronic Device for Overactive Bladder in Women
11 déc. 2024 15h18 HE
|
FemPulse
SAN FRANCISO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- FemPulse™ announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II...